Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.47 |
| ▸ | ADH5 | P11766 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16659027 | 0.89 | SCN9A (0.55) | SCN9ASCN5A | |
| SCHEMBL20794151 | 0.88 | ADH5 (0.50) | SCN9ASCN5AADH5 | |
| SCHEMBL14889895 | 0.84 | SCN9A (0.49) | SCN9ASCN5A | |
| SCHEMBL16651019 | 0.84 | ADH5 (0.48) | SCN9AADH5 | |
| SCHEMBL15526486 | 0.84 | ADH5 (0.48) | SCN9AADH5 | |
| SCHEMBL19183526 | 0.83 | SCN9A (0.53) | SCN9ASCN5A | |
| SCHEMBL20780261 | 0.82 | CETP (0.44) | SCN9ASCN5AADH5 | |
| SCHEMBL19183560 | 0.81 | SCN9A (0.46) | SCN9ASCN5A | |
| SCHEMBL20794132 | 0.79 | CETP (0.62) | SCN5A | |
| SCHEMBL20613143 | 0.78 | CETP (0.58) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353101-B2 | Cyclic amine substituted heterocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2934519-A1 | THERAPEUTIC THIAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2844252-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2014099834-A1 | THERAPEUTIC THIAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013165854-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111866-A1 | CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS | CETP, APOB, MTTP | SCN9A 2592/4885SCN5A 2838/4885ADH5 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.